Cigna Lowers Out-of-Pocket Costs for Popular Weight-Loss Drugs
Cigna is reducing monthly out-of-pocket costs to $200 for patients using weight-loss drugs Wegovy and Zepbound. These medications, from Novo Nordisk and Eli Lilly, typically cost much more. The $200 co-pays contribute to deductibles, aiding patients financially. Demand for these drugs soared amidst shortages, leading to sales of compounded versions.
Cigna has announced it will limit out-of-pocket costs to $200 per month for patients on the weight-loss medications Wegovy and Zepbound. This initiative is part of an add-on to Cigna's pharmacy benefit management plans, as revealed by the company on Wednesday.
Novo Nordisk and Eli Lilly's drugs, Wegovy and Zepbound, boast list prices of up to $1,000. However, they're often available at reduced rates on the manufacturers' websites. The $200 co-pays will contribute toward a patient's deductible, explained Harold Carter, a senior vice president at Evernorth.
Clinical trials indicate Wegovy and Zepbound can cut body weight by 15% to 20%, functioning by slowing digestion and extending satiety. Shortages sparked increased sales of compounded versions from firms like Hims & Hers, Noom, and Weight Watchers. This situation is expected to shift as the FDA's allowance for compounded copies ends May 22.
(With inputs from agencies.)
- READ MORE ON:
- Cigna
- weight-loss
- drugs
- Wegovy
- Zepbound
- healthcare
- costs
- prescription
- insurance
- clinical trials
ALSO READ
A Vision from the Frontlines of Shekar Hospital reimagines Universal Insurance for India’s growing demand for quality healthcare.
Rising Liver Disease Costs: Why Health Insurance is a Financial Lifesaver
Cuba's Internet Dilemma: Balancing Costs Amid Crisis
British Equities Surge as Healthcare and Mining Lead the Way
Apollo Medicine Celebrates 20 Years of Healthcare Innovation
Google News